Literature DB >> 22082479

miR221/222 in cancer: their role in tumor progression and response to therapy.

M Garofalo1, C Quintavalle, G Romano, C M Croce, G Condorelli.   

Abstract

miRNAs are small non-coding RNAs of ~24 nt that can block mRNA translation and/or negatively regulate its stability. There is a large body of evidence that dysregulation of miRNAs is a hallmark of cancer. miRNAs are often aberrantly expressed and their function is linked to the regulation of oncogenes and/or tumor suppressor genes involved in cell signaling pathway. miR-221 and miR-222 are two highly homologous microRNAs, whose upregulation has been recently described in several types of human tumors. miR-221/222 have been considered to act as oncogenes or tumor suppressors, depending on tumor system. Silencing oncomiRs or gene therapy approaches, based on re-expression of miRNAs that are down-regulated in cancer cells, could represent a novel anti-tumor approach for integrated cancer therapy. Here we will review the role of miR-221/222 in cancer progression and their use as prognostic and therapeutic tools in cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22082479      PMCID: PMC3673714          DOI: 10.2174/156652412798376170

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  54 in total

Review 1.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  PUMA is a novel target of miR-221/222 in human epithelial cancers.

Authors:  Chunzhi Zhang; Junxia Zhang; Anlin Zhang; Yingyi Wang; Lei Han; Yongping You; Peiyu Pu; Chunsheng Kang
Journal:  Int J Oncol       Date:  2010-12       Impact factor: 5.650

3.  MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.

Authors:  X Rao; G Di Leva; M Li; F Fang; C Devlin; C Hartman-Frey; M E Burow; M Ivan; C M Croce; K P Nephew
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

4.  miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222.

Authors:  M Acunzo; R Visone; G Romano; A Veronese; F Lovat; D Palmieri; A Bottoni; M Garofalo; P Gasparini; G Condorelli; M Chiariello; C M Croce
Journal:  Oncogene       Date:  2011-06-27       Impact factor: 9.867

5.  miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ.

Authors:  C Quintavalle; M Garofalo; C Zanca; G Romano; M Iaboni; M del Basso De Caro; J C Martinez-Montero; M Incoronato; G Nuovo; C M Croce; G Condorelli
Journal:  Oncogene       Date:  2011-07-11       Impact factor: 9.867

6.  Clinical significance of miR-221 and its inverse correlation with p27Kip¹ in hepatocellular carcinoma.

Authors:  Xinhui Fu; Qian Wang; Jingsong Chen; Xiaohui Huang; Xilin Chen; Liangqi Cao; Haoxiang Tan; Wen Li; Longjuan Zhang; Jiong Bi; Qiao Su; Lianzhou Chen
Journal:  Mol Biol Rep       Date:  2010-02-10       Impact factor: 2.316

7.  Adenovirus-mediated shRNAs for co-repression of miR-221 and miR-222 expression and function in glioblastoma cells.

Authors:  Xuan Wang; Lei Han; Anling Zhang; Guangxiu Wang; Zhifan Jia; Yang Yang; Xiao Yue; Peiyu Pu; Changhong Shen; Chunsheng Kang
Journal:  Oncol Rep       Date:  2011-01       Impact factor: 3.906

8.  Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.

Authors:  Igor P Pogribny; Jody N Filkowski; Volodymyr P Tryndyak; Andrey Golubov; Svitlana I Shpyleva; Olga Kovalchuk
Journal:  Int J Cancer       Date:  2010-10-15       Impact factor: 7.396

9.  MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias.

Authors:  George Adrian Calin; Chang-Gong Liu; Cinzia Sevignani; Manuela Ferracin; Nadia Felli; Calin Dan Dumitru; Masayoshi Shimizu; Amelia Cimmino; Simona Zupo; Mariella Dono; Marie L Dell'Aquila; Hansjuerg Alder; Laura Rassenti; Thomas J Kipps; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-29       Impact factor: 11.205

10.  The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity.

Authors:  W Bode; P Reinemer; R Huber; T Kleine; S Schnierer; H Tschesche
Journal:  EMBO J       Date:  1994-03-15       Impact factor: 11.598

View more
  144 in total

1.  Serum microRNA profiles as prognostic or predictive markers in the multimodality treatment of patients with gastric cancer.

Authors:  Leila Sisic; Daniel Vallböhmer; Nikolas H Stoecklein; Susanne Blank; Thomas Schmidt; Christiane Driemel; Birte Möhlendick; Wolfram T Knoefel; Margarete Odenthal; Katja Ott
Journal:  Oncol Lett       Date:  2015-06-09       Impact factor: 2.967

Review 2.  Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Yiwei Li; Aamir Ahmad; Shadan Ali; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Curr Stem Cell Res Ther       Date:  2014-01       Impact factor: 3.828

3.  Expression of miR-221 in colon cancer correlates with prognosis.

Authors:  Ke Cai; Feng Shen; Jun-Hui Cui; Yong Yu; Hai-Qiang Pan
Journal:  Int J Clin Exp Med       Date:  2015-02-15

4.  microRNA-221 restricts human cytomegalovirus replication via promoting type I IFN production by targeting SOCS1/NF-κB pathway.

Authors:  Beizhan Yan; Huimin Ma; Shuting Jiang; Jingli Shi; Ziyi Yang; Weiyan Zhu; Cunquan Kong; Lin Chen; Hui Yan; Cuixia Ma
Journal:  Cell Cycle       Date:  2019-09-24       Impact factor: 4.534

5.  MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27.

Authors:  Yue-Feng Yang; Fei Wang; Jun-Jie Xiao; Yang Song; Ying-Ying Zhao; Yan Cao; Yi-Hua Bei; Chang-Qing Yang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

6.  The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression.

Authors:  Paula Mussnich; Daniela D'Angelo; Vincenza Leone; Carlo Maria Croce; Alfredo Fusco
Journal:  Mol Oncol       Date:  2013-01-17       Impact factor: 6.603

7.  Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.

Authors:  Jesús García-Donas; Benoit Beuselinck; Lucía Inglada-Pérez; Osvaldo Graña; Patrick Schöffski; Agnieszka Wozniak; Oliver Bechter; Maria Apellániz-Ruiz; Luis Javier Leandro-García; Emilio Esteban; Daniel E Castellano; Aranzazu González Del Alba; Miguel Angel Climent; Susana Hernando; José Angel Arranz; Manuel Morente; David G Pisano; Mercedes Robledo; Cristina Rodriguez-Antona
Journal:  JCI Insight       Date:  2016-07-07

8.  Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma.

Authors:  J Qi; J Wang; H Katayama; S Sen; S M Liu
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

9.  MicroRNA-155 expression inversely correlates with pathologic stage of gastric cancer and it inhibits gastric cancer cell growth by targeting cyclin D1.

Authors:  Zhijun Ma; Yulan Ma; Qinghua Xia; Yong Li; Ruidong Li; Weilong Chang; Jinhuang Chen; Zhengwei Leng; Kaixiong Tao
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-08       Impact factor: 4.553

Review 10.  miR-221/222: promising biomarkers for breast cancer.

Authors:  Wei-Xian Chen; Qing Hu; Man-Tang Qiu; Shan-Liang Zhong; Jin-Jin Xu; Jin-Hai Tang; Jian-Hua Zhao
Journal:  Tumour Biol       Date:  2013-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.